Clinical pharmacology and therapeutics
Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma.
Ruben Malmberg, Maaike M Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A Basak, Esther Oomen-de Hoop, Astrid A M van der Veldt, Arjen Joosse, Roelof W F van Leeuwen, Ron H J Mathijssen
Published: 202510.1002/cpt.70182
Abstract
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing re…
Preview only. Read the full abstract at the source